- Home
- ESLA vs SCLX Comparison
ESLA vs SCLX Comparison
Compare ESLA & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLA
- SCLX
- Stock Information
- Founded
- ESLA 2021
- SCLX 2011
- Country
- ESLA United States
- SCLX United States
- Employees
- ESLA N/A
- SCLX N/A
- Industry
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- ESLA Health Care
- SCLX Health Care
- Exchange
- ESLA Nasdaq
- SCLX Nasdaq
- Market Cap
- ESLA 35.5M
- SCLX 35.7M
- IPO Year
- ESLA N/A
- SCLX N/A
- Fundamental
- Price
- ESLA $0.98
- SCLX $18.29
- Analyst Decision
- ESLA Strong Buy
- SCLX Strong Buy
- Analyst Count
- ESLA 1
- SCLX 3
- Target Price
- ESLA $16.00
- SCLX $367.50
- AVG Volume (30 Days)
- ESLA 9.7K
- SCLX 290.7K
- Earning Date
- ESLA 08-12-2025
- SCLX 08-13-2025
- Dividend Yield
- ESLA N/A
- SCLX N/A
- EPS Growth
- ESLA N/A
- SCLX N/A
- EPS
- ESLA N/A
- SCLX N/A
- Revenue
- ESLA N/A
- SCLX $44,236,000.00
- Revenue This Year
- ESLA N/A
- SCLX $89.26
- Revenue Next Year
- ESLA N/A
- SCLX $203.95
- P/E Ratio
- ESLA N/A
- SCLX N/A
- Revenue Growth
- ESLA N/A
- SCLX N/A
- 52 Week Low
- ESLA $0.63
- SCLX $3.60
- 52 Week High
- ESLA $1.78
- SCLX $43.05
- Technical
- Relative Strength Index (RSI)
- ESLA 62.41
- SCLX 60.97
- Support Level
- ESLA $0.84
- SCLX $15.61
- Resistance Level
- ESLA $0.99
- SCLX $20.41
- Average True Range (ATR)
- ESLA 0.05
- SCLX 2.22
- MACD
- ESLA 0.01
- SCLX -0.19
- Stochastic Oscillator
- ESLA 97.44
- SCLX 55.40
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.